Skip to main content
QB

Quadrant Biosciences

Quadrant Biosciences utilizes saliva-based molecular diagnostics to detect neurological disorders such as autism and Parkinson's disease through epigenetic analysis. Their technology addresses the need for early and accessible diagnostic solutions, improving outcomes for children and families affected by these conditions.

Founded 2015343K+ followers
Updated 4 months ago

Funding

$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Diagnosing neurological disorders like autism and Parkinson's disease often involves invasive procedures and lengthy observation periods, leading to delayed diagnoses and increased stress for patients and families. Traditional diagnostic methods can also be subjective and lack the precision needed for early intervention and personalized treatment plans.

Solution

Quadrant Biosciences offers saliva-based molecular diagnostic tools designed for the early detection and monitoring of neurological disorders. Their epigenetic analysis technology provides a non-invasive method for identifying biomarkers associated with conditions like autism spectrum disorder (ASD) and Parkinson's disease. By analyzing saliva samples, the company aims to provide clinicians with objective data to aid in diagnosis, treatment planning, and ongoing monitoring of disease progression. Their Autism Analytica platform streamlines the assessment process, standardizes workflows, and elevates the quality of care through software solutions designed for clinicians, organizations, and caregivers.

Target Audience

Quadrant Biosciences primarily serves clinicians, physicians, and clinical researchers focused on neurological disorders, as well as families and individuals seeking early and accurate diagnostic solutions. Their Autism Analytica platform targets clinicians, healthcare organizations, and caregivers involved in autism assessment and treatment.

Features

  • Saliva-based molecular diagnostics for early detection of neurological disorders
  • Epigenetic analysis to identify biomarkers associated with autism and Parkinson's disease
  • Non-invasive sample collection, reducing patient discomfort and improving accessibility
  • Autism Analytica platform for streamlining assessments and standardizing workflows
  • Virtual IPM (Integrated Practice Management) platform designed by clinicians for clinicians
  • Medical necessity tool that uses child characteristics and assessment data to help drive treatment planning
  • Secure portal for clinicians to access, review, and export system-generated reports
  • Assessment battery tailored to individual child characteristics
This profile is AI-generated and may contain inaccuracies.